Spot on assessment in the Emerging article vis a v
Post# of 154991
(Total Views: 347)
Posted On: 07/26/2021 4:21:47 PM
Spot on assessment in the Emerging article vis a vis Brazil. I've been saying it'll goose the share price for a while now, because Brazil trial starting has not been priced in. In fact, I think pessimism about the Brazil trial is partly why the price is so depressed...
Quote:
The Brazilian trials are imminent. There is movement on the Brazailian clinical trial websites that show an increase in the number of trial sites. They also show ethics approval on July 22, 2021. Many investors do not believe this will happen because the company keeps saying it will happen “soon.” There are many investors waiting on the fence to buy on the news because then they know within 2 months, at least interim results will be released. Those interim results should be a slam dunk for meeting their endpoint and therefore approval under an Emergency Use Authorization (EUA). Many investors know this so dosing the first patient in the trial should be a market moving catalyst. The company said that they would dose the first patient by the end of the month so their credibility is also on the line and many investors are watching from the sidelines. The value investors are the one gobbling shares at the moment because they understand the trajectory of news is going to crescendo into October.
(7)
(0)